Production & Manufacturing

In the biopharma industry, selecting the right contract development and manufacturing organization (CDMO) is pivotal to a successful pharmaceutical development journey. This decision hinges on two critical factors: a customer-centric approach and team cohesion. In this blog, we explore...

Biovian, a leading contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, has announced a major investment of over €50 million to expand its manufacturing facility in Turku, Finland. This investment reflects Biovian’s commitment to meeting the growing demand for...

A recent article published in the Journal of Membrane Science presents a new approach for implementing a robust single-pass tangential flow filtration (SP-TFF) operation in biomanufacturing. The authors introduce a process analytical technology (PAT)-based strategy that integrates and continuously...

The global cell and gene therapy Contract Development and Manufacturing Organization (CDMO) services market, which was valued at USD 5,193.7 million in 2022, is expected to grow at a CAGR of 17.5% during the forecast period from 2023 to...

CDMOs (contract development and manufacturing organizations) are facing challenges due to the increasing number of companies preparing to scale up their cell and gene therapy manufacturing for Phase III trials and commercialization. While physical capacity has been blamed, the...

The World Health Organisation as well as the Republic of South Korea have gone ahead and inked a MoU so as to establish a worldwide training hub when it comes to biomanufacturing. The worldwide training centre will go on...

uBriGene, a cell & gene therapy contract development and manufacturing organization (CDMO), is expanding into the US market with the acquisition of a state-of-the-art GMP manufacturing facility from NASDAQ-listed company Mustang Bio, Inc. The cell & gene therapy (CGT) CDMO...